HAS statement on AstraZeneca vaccine in response to new vaccine safety concerns - 8 April, 2021

The HAS recommends using the mRNA vaccines currently available (COMIRNATY or Covid-19 Moderna vaccine) for the administration (with the individual's agreement) of the second dose in people under 55 years of age who have received a first dose of the AstraZeneca vaccine (newly called VAXZEVRIA vaccine), with an interval of 12 weeks between doses.